Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 18 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil diethanolamine; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
Interventions: bortezomib; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Urinary Incontinence
Interventions: Care planning using TENA Identifi sensor wear data, Care planning without using TENA Identifi sensor wear data; Other
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 55 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Chesapeake, Virginia • Norfolk, Virginia • Virginia Beach, Virginia

Conditions: Head and Neck Cancer
Interventions: Gemcitabine, Pemetrexed, Carboplatin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain, Anxiety
Interventions: Music; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obstructive Sleep Apnea
Interventions: Lung-function spirometry test, Overnight sleep test; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Chronic Idiopathic Urticaria
Interventions: Placebo, Omalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 36
States / cities: La Jolla, California • Los Angeles, California • Redwood City, California + 31 more

Conditions: Alcoholic Intoxication, Alcoholism, Healthy
Interventions: Not listed
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years and older
Enrollment: 2,220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: TAK-228, Letrozole; Drug
Lead sponsor: Gary Schwartz; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Male Urogenital Diseases, Genital Diseases, Male, Prostatic Disease, Prostatic Hyperplasia
Interventions: SoracteLite(TM) TPLA for BPH; Device
Lead sponsor: Urological Research Network, LLC; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Ischemic Cardiomyopathy, Dilated Cardiomyopathy, Inflammation, Sudden Cardiac Death
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Thoracoabdominal Aortic Aneurysm
Interventions: Thoracoabdominal Aortic Aneurysm Repair; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic Melanoma
Interventions: TLPLDC Vaccine; Drug
Lead sponsor: Elios Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 4 more

Conditions: Liver Transplant Rejection, Liver Transplant Failure and Rejection
Interventions: N/A-Observational Study; Other
Lead sponsor: St. Louis University; Other
Eligibility: 1 Year and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Venous Thromboembolism, Thoracic Surgery, Esophageal Cancer
Interventions: Not listed
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • Cleveland, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Clinician communication training, Patient activation, RA Medication summary guide and RA Choice; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: San Francisco, California • Wilmington, Delaware • Portland, Oregon + 1 more

Conditions: Portal Hypertension
Interventions: Placebo, Cobiprostone; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Vitamin D Deficiency
Interventions: Tri-Vi-Sol; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 2 Hours
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Narcolepsy
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Melanoma
Interventions: LTX-315 in combination with pembrolizumab; Combination Product
Lead sponsor: Lytix Biopharma AS; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: New York, New York • Charlotte, North Carolina • Pittsburgh, Pennsylvania + 1 more

Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer, Urothelial Carcinoma (UC), Cholangiocarcinoma, Mesothelioma, Gallbladder Cancer, Ovarian Cancer
Interventions: MDX2001; Drug
Lead sponsor: ModeX Therapeutics, An OPKO Health Company; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • Boston, Massachusetts + 3 more

Conditions: Duct Cell Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: gemcitabine hydrochloride, fluorouracil, radiation therapy, laboratory biomarker analysis; Drug · Radiation · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Myopia, Astigmatism
Interventions: Topography Guided LASIK Surgery, Small Incision Lenticule Extraction Surgery; Device
Lead sponsor: Hoopes Vision; Other
Eligibility: 22 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Draper, Utah

Search by objective public record fields.

Patients With NMDA Biomarker Data Following Cardiac Surgery

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

A Pilot Clinical Trial of TENA Identifi in the Nursing Home Setting

Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients

Music and Local Anesthesia During Dermatologic Procedures

Effect of Interscalene Block on Obstructive Sleep Apnea in Shoulder Surgery Patients

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

Screening Evaluation for Studies of the National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

Office Based Transperineal Laser Ablation for Benign Prostatic Hyperplasia HYPERPLASIA

Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death

Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients

Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection

Rheumatoid Arthritis Shared Decision Making

Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

Impact of Vitamin D Status on Bones in Breastfed Infants

Body Weight Regulation in Patients With Narcolepsy

Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer

Contralateral Study of Topography Guided LASIK Versus Small Incision Lenticule Extraction